Critical Survey: Seer (NASDAQ:SEER) & Immunovant (NASDAQ:IMVT)

Immunovant (NASDAQ:IMVT) and Seer (NASDAQ:SEER) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, risk, dividends, valuation, analyst recommendations, profitability and earnings.

Analyst Recommendations

This is a summary of recent recommendations and price targets for Immunovant and Seer, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immunovant	1	3	6	1	2.64
Seer	1	0	0	0	1.00

Immunovant currently has a consensus target price of $30.78, suggesting a potential upside of 17.65%. Given Immunovant’s stronger consensus rating and higher possible upside, equities analysts clearly believe Immunovant is more favorable than Seer.

Insider & Institutional Ownership

47.1% of Immunovant shares are owned by institutional investors. Comparatively, 75.2% of Seer shares are owned by institutional investors. 1.8% of Immunovant shares are owned by insiders. Comparatively, 11.3% of Seer shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Profitability

This table compares Immunovant and Seer’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Immunovant	N/A	-81.55%	-73.09%
Seer	-484.51%	-25.88%	-23.07%

Risk & Volatility

Immunovant has a beta of 0.57, indicating that its stock price is 43% less volatile than the S&P 500. Comparatively, Seer has a beta of 1.6, indicating that its stock price is 60% more volatile than the S&P 500.

Earnings and Valuation

This table compares Immunovant and Seer”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immunovant	N/A	N/A	-$413.84 million	($2.84)	-9.21
Seer	$14.17 million	7.38	-$86.60 million	($1.36)	-1.38

Seer has higher revenue and earnings than Immunovant. Immunovant is trading at a lower price-to-earnings ratio than Seer, indicating that it is currently the more affordable of the two stocks.

Summary

Seer beats Immunovant on 9 of the 14 factors compared between the two stocks.

About Immunovant

Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that target the neonatal fragment crystallizable receptor for the treatment of myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy, and Graves diseases, as well as warm autoimmune hemolytic anemia. The company is headquartered in New York, New York. Immunovant, Inc. operates as a subsidiary of Roivant Sciences Ltd.

About Seer

Seer, Inc., a life sciences company, engages in developing and commercializing products to decode the biology of the proteome. It develops Proteograph Product Suite, an integrated solution that includes proprietary engineered nanoparticles, consumables, automation instrumentation, and software to perform proteomic analysis to provide a solution that can be incorporated by nearly any lab for research use only. The company intends to sell its products for research use only, which cover academic institutions, life sciences, and research laboratories, as well as biopharmaceutical and biotechnology companies for non-diagnostic and non-clinical purposes. It operates in China, Australia, Eastern Europe, Israel, and Japan. The company was formerly known as Seer Biosciences, Inc. and changed its name to Seer, Inc. in July 2018. Seer, Inc. was incorporated in 2017 and is headquartered in Redwood City, California.